Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs.
According to Aprea, the company has strengthened its global IP portfolio with 28 issued and 30 pending patents. The IP covering Aprea’s WEE1 kinase inhibitor program includes two pending U.S. patent applications, one pending U.S. provisional application, two granted non-U.S. patents (Australia and Korea), and 12 pending non-U.S. patent applications. The WEE1 family of applications, if granted, will expire in 2047, not including any regulatory exclusivities that may be awarded.
In a statement, Oren Gilad, PhD, president and CEO of Aprea, commented, “Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine. A strong global intellectual property portfolio is a critical component of our strategy, supporting the advancement of potentially best in class oncology therapies while protecting the long-term value of our programs. We remain focused on strengthening our intellectual property position as we advance our pipeline and pursue new treatment options for patients with difficult-to-treat cancers.”
